Evox Therapeutics: Funding, Investors & Team (Aug 2026)
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.
Evox Therapeutics has raised $96.6M across 1 funding round on record, the most recent a Series C of $96.6M announced in Feb 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Evox Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2021.
Evox Therapeutics Funding Rounds
Evox Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Evox Therapeutics Funding Compared to Other Biotechnology Startups
Evox Therapeutics' latest round of $96.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evox Therapeutics in Biotechnology and Oxford
Companies Similar to Evox Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Evox Therapeutics Funding FAQs
What does Evox Therapeutics do?
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.
How much funding has Evox Therapeutics raised?
Evox Therapeutics has raised $96.6M across 1 round on record. The most recent is a Series C of $96.6M announced in Feb 2021.
When did Evox Therapeutics last raise funding?
Evox Therapeutics' most recent funding round on record is a Series C of $96.6M, announced in Feb 2021.
Who is the CEO of Evox Therapeutics?
Antonin de Fougerolles is listed as CEO at Evox Therapeutics.
Where is Evox Therapeutics headquartered?
Evox Therapeutics is based in Oxford, Oxfordshire, United Kingdom.
How many employees does Evox Therapeutics have?
Evox Therapeutics is in the 101-250 employee band.
How does Evox Therapeutics' funding compare to other Biotechnology startups?
Evox Therapeutics' latest round of $96.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Evox Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evox Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.